Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations.
Elderly or frail patients are often excluded from clinical trials. As a result, clinical outcome of these patients may differ from those obtained in trials. This situation may also hold true for patients who have severe concomitant diseases such as renal, hepatic, or cardiac dysfunction. Being aware of the wide range of clinical situations that a specialist may face is important to ensure that under any circumstances, the patient will receive the best treatment possible. The Spanish Oncology Genitourinary Group issued its first public statement on recommendations for the optimal management of advanced renal cell carcinoma (RCC). However, some issues remained unsolved. In this report, we discuss the current role of Medical Oncology in the treatment of patients with advanced RCC and review the management of special patient populations, such as elderly or patients with concomitant diseases.
Calvo
Emiliano
E
Hospital de Madrid-CIOCC, Madrid, Spain.
Maroto
Pablo
P
del Muro
Xavier García
XG
Climent
Miguel Angel
MA
González-Larriba
José Luis
JL
Esteban
Emilio
E
López
Rafael
R
Paz-Ares
Luis
L
Bellmunt
Joaquim
J
Castellano
Daniel
D
D002292:Carcinoma, Renal Cell / Q000208:ethnology / Q000556:secondary / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000208:ethnology / Q000473:pathology / Q000628:therapy*